Suzanne M Cadarette1, Andrea M Burden. 1. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada. s.cadarette@utoronto.ca
Abstract
PURPOSE OF REVIEW: Osteoporosis is a major public health issue resulting in considerable fracture-related morbidity. Although effective treatment exists, adherence to osteoporosis pharmacotherapy is suboptimal and linked to reduced drug effectiveness. In this paper, we review methods of measuring and improving adherence to osteoporosis pharmacotherapy. RECENT FINDINGS: Most patients will stop osteoporosis pharmacotherapy, yet the majority who discontinue will reinitiate treatment after an extended gap. The key to improving adherence to osteoporosis pharmacotherapy is to reduce the number and length of gaps in treatment. Multifaceted and individualized interventions may help to improve adherence. New strategies aimed at identifying patients likely to stop therapy may also facilitate the development of targeted interventions. SUMMARY: Adherence to osteoporosis pharmacotherapy is suboptimal with short periods of persistence and lengthy gaps in therapy. Regular communication regarding the importance of continued therapy is critical. More research to help identify risk profiles of patients likely to become nonadherent, targeted multifaceted interventions to maximize adherence to therapy, and data to support when patients may safely consider a physician directed drug holiday is needed.
PURPOSE OF REVIEW: Osteoporosis is a major public health issue resulting in considerable fracture-related morbidity. Although effective treatment exists, adherence to osteoporosis pharmacotherapy is suboptimal and linked to reduced drug effectiveness. In this paper, we review methods of measuring and improving adherence to osteoporosis pharmacotherapy. RECENT FINDINGS: Most patients will stop osteoporosis pharmacotherapy, yet the majority who discontinue will reinitiate treatment after an extended gap. The key to improving adherence to osteoporosis pharmacotherapy is to reduce the number and length of gaps in treatment. Multifaceted and individualized interventions may help to improve adherence. New strategies aimed at identifying patients likely to stop therapy may also facilitate the development of targeted interventions. SUMMARY: Adherence to osteoporosis pharmacotherapy is suboptimal with short periods of persistence and lengthy gaps in therapy. Regular communication regarding the importance of continued therapy is critical. More research to help identify risk profiles of patients likely to become nonadherent, targeted multifaceted interventions to maximize adherence to therapy, and data to support when patients may safely consider a physician directed drug holiday is needed.
Authors: Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson Journal: J Bone Miner Res Date: 2007-03 Impact factor: 6.741
Authors: Richard A Hansen; Stacie B Dusetzina; Rosalie C Dominik; Bradley N Gaynes Journal: Pharmacoepidemiol Drug Saf Date: 2010-01 Impact factor: 2.890
Authors: T Gleeson; M D Iversen; J Avorn; A M Brookhart; J N Katz; E Losina; F May; A R Patrick; W H Shrank; D H Solomon Journal: Osteoporos Int Date: 2009-06-05 Impact factor: 4.507
Authors: Richard A Hansen; Mimi M Kim; Liping Song; Wanzhu Tu; Jingwei Wu; Michael D Murray Journal: Ann Pharmacother Date: 2009-03-03 Impact factor: 3.154
Authors: Elaine Lau; Alexandra Papaioannou; Lisa Dolovich; Jonathan Adachi; Anna M Sawka; Sheri Burns; Kalpana Nair; Anjali Pathak Journal: Can Fam Physician Date: 2008-03 Impact factor: 3.275
Authors: Catherine MacLean; Sydne Newberry; Margaret Maglione; Maureen McMahon; Veena Ranganath; Marika Suttorp; Walter Mojica; Martha Timmer; Alicia Alexander; Melissa McNamara; Sheetal B Desai; Annie Zhou; Susan Chen; Jason Carter; Carlo Tringale; Di Valentine; Breanne Johnsen; Jennifer Grossman Journal: Ann Intern Med Date: 2007-12-17 Impact factor: 25.391
Authors: Michael J Stirratt; Jeffrey R Curtis; Maria I Danila; Richard Hansen; Michael J Miller; C Ann Gakumo Journal: J Gen Intern Med Date: 2018-02 Impact factor: 5.128
Authors: Sylvie F Hall; Stephanie W Edmonds; Yiyue Lou; Peter Cram; Douglas W Roblin; Kenneth G Saag; Nicole C Wright; Michael P Jones; Fredric D Wolinsky Journal: J Am Pharm Assoc (2003) Date: 2017-06-08